1. Home
  2. NGNE vs VLRS Comparison

NGNE vs VLRS Comparison

Compare NGNE & VLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$25.43

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Logo Controladora Vuela Compania de Aviacion S.A.B. de C.V.

VLRS

Controladora Vuela Compania de Aviacion S.A.B. de C.V.

N/A

Current Price

$7.94

Market Cap

793.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
VLRS
Founded
2003
2005
Country
United States
Mexico
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Air Freight/Delivery Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
793.2M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
NGNE
VLRS
Price
$25.43
$7.94
Analyst Decision
Strong Buy
Buy
Analyst Count
10
13
Target Price
★ $77.88
$8.84
AVG Volume (30 Days)
342.8K
★ 908.5K
Earning Date
11-20-2026
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 0.93
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$27.83
Revenue Next Year
N/A
$7.37
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$15.93
$5.46
52 Week High
$43.66
$10.80

Technical Indicators

Market Signals
Indicator
NGNE
VLRS
Relative Strength Index (RSI) 47.84 78.15
Support Level $24.88 $6.95
Resistance Level $28.47 $7.93
Average True Range (ATR) 2.50 0.35
MACD 0.38 0.24
Stochastic Oscillator 35.88 98.58

Price Performance

Historical Comparison
NGNE
VLRS

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About VLRS Controladora Vuela Compania de Aviacion S.A.B. de C.V.

Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).

Share on Social Networks: